Kirjoita osake tai kryptovaluutta hakupalkkiin saadaksesi yhteenvedon
Biocon Limited
BIOCONBiocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, and bevacizumab. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer good, and agrochemical companies. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India. Address: 20th KM Hosur Road, Bengaluru, India, 560100
Analytics
WallStreetin tavoitehinta
27 962.48 INRP/E-suhde
26.7304Osinkotuotto
0.15 %Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Avainluvut BIOCON
Osinkoanalytiikka BIOCON
Osinkojen kasvu 5 vuoden aikana
200 %Jatkuva kasvu
1 vuosiMaksusuhde 5 vuoden keskiarvo
18 %Osinkohistoria BIOCON
Osakkeen arvostus BIOCON
Talousasiat BIOCON
Tuloksia | 2019 | Dynamiikka |